This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
  • Home
  • /
  • Drugs
  • /
  • V
  • /
  • Vitalipid N
  • /
  • Vitalipid N .ALPHA.-TOCOPHEROL, DL- .7 [iU]/mL Fresenius Kabi USA, LLC
FDA Drug information

Vitalipid N

Read time: 1 mins
Marketing start date: 04 Apr 2025
...
 

Summary of product characteristics


Effective Time

20230907

Version

2

Spl Product Data Elements

Vitalipid N VITAMIN A PALMITATE, Ergocalciferol, .ALPHA.-TOCOPHEROL, DL-, PHYTONADIONE VITAMIN A PALMITATE VITAMIN A Ergocalciferol Ergocalciferol .ALPHA.-TOCOPHEROL, DL- .ALPHA.-TOCOPHEROL, DL- PHYTONADIONE PHYTONADIONE EGG PHOSPHOLIPIDS GLYCERIN SODIUM HYDROXIDE WATER SOYBEAN OIL Vitalipid N VITAMIN A PALMITATE, Ergocalciferol, .ALPHA.-TOCOPHEROL, DL-, PHYTONADIONE VITAMIN A PALMITATE VITAMIN A Ergocalciferol Ergocalciferol .ALPHA.-TOCOPHEROL, DL- .ALPHA.-TOCOPHEROL, DL- PHYTONADIONE PHYTONADIONE EGG PHOSPHOLIPIDS GLYCERIN SODIUM HYDROXIDE WATER SOYBEAN OIL Vitalipid N VITAMIN A PALMITATE, Ergocalciferol, .ALPHA.-TOCOPHEROL, DL-, PHYTONADIONE VITAMIN A PALMITATE VITAMIN A Ergocalciferol Ergocalciferol .ALPHA.-TOCOPHEROL, DL- .ALPHA.-TOCOPHEROL, DL- PHYTONADIONE PHYTONADIONE EGG PHOSPHOLIPIDS GLYCERIN SOYBEAN OIL SODIUM HYDROXIDE WATER

Brand Name

Vitalipid N

Generic Name

VITAMIN A PALMITATE, Ergocalciferol, .ALPHA.-TOCOPHEROL, DL-, PHYTONADIONE

Product Ndc

65219-337

Product Type

HUMAN PRESCRIPTION DRUG

Route

INTRAVENOUS

Package Label Principal Display Panel

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID ® N Infant 10 mL Ampule Label Vitalipid ® N Infant 10 ml Concentrate for emulsion for infusion For intravenous infusion PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID® N Infant 10 mL Ampule Label

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.